CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver

Cancer Research

Volumn 57, Issue 16, 1997, Pages 3402-3406

  Dehal, Shangara S ^a   Kupfer, David ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME B5; CYTOCHROME P450; TAMOXIFEN; TAMOXIFEN DERIVATIVE;

ARTICLE; DEMETHYLATION; DNA ADDUCT; DRUG HYDROXYLATION; DRUG METABOLISM; HUMAN; HUMAN CELL; HYDROXYLATION; LIVER METABOLISM; LIVER MICROSOME; PRIORITY JOURNAL;

CYTOCHROME P-450 CYP2D6; ESTROGEN ANTAGONISTS; HUMANS; HYDROXYLATION; MICROSOMES, LIVER; TAMOXIFEN;

EID: 0030812209     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Jordan, V. C. A current view of tamoxifen for the treatment and prevention of breast cancer. Br. J. Pharmacol., 110: 507-517, 1993
2. Chlebowski, R. J., Butler. J., Nelson, A., and Lillington, L. Breast cancer chemoprevention. Tamoxifen: current issues and future perspective. Cancer (Phila.), 72: 1032-1037, 1993.
3. Fisher, B., and Redmond, C. New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent. J. Natl. Cancer Inst., 83: 1278-1280, 1991.
4. Jordan, V. C. The role of tamoxifen in the treatment and prevention of breast cancer. Curr. Probl. Cancer, 16: 129-176, 1992.
5. Killackey, M. A., Hakes, T. B., and Price, V. K. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat. Rep., 69: 237-238, 1985.
6. Fornander, T., Cedermark, B., Matteson, A., Skoog, L., Theve, T., Askergren, J., Rutqvist, L. E., Glas, U., Silljverswaard, C., Somell, A., Wilking, N., and Hjolmar, M. J. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet, 1: 117-119, 1989.
7. Fendel, K. C., and Zimniski, S. J. Role of tamoxifen in the induction of hormone-independent rat mammary tumors. Cancer Res., 52: 235-237, 1992.
8. Williams, G. M., Iatropoulos, M. J., Djordjevic, M. W., and Kaltenberg, O. P. The triphenylethylene drug tamoxifen is a strong carcinogen in the rat. Carcinogenesis (Lond.), 14: 315-317, 1993.
9. Vancutsem, P. M., Lazarus, P., and Williams, G. M. Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen. Cancer Res., 54: 3864-3867, 1994.
10. Dehal, S. S., and Kupfer, D. Evidence that the catechol 3,4-dihydroxy tamoxifen is a proximate intermediate to the reactive species binding covalently to proteins. Cancer Res., 56: 1283-1290, 1996.
11. Mani, C., and Kupfer, D. Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of flavin-containing monooxygenases in tamoxifen activation. Cancer Res., 51: 6052-6058, 1991.
12. Mani, C., Pierce, R., Parkinson, A., and Kupfer, D. Involvement of cytochrome P-450 3A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis (Lond.), 15: 2715-2720, 1994.
13. Han, X-L., and Liehr, J. G. Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res., 52: 1360-1363, 1992.
14. White, I. N. H., de Matteis, F., Davies, A., Smith, L. L., Crofton-Sleigh, C., Venitt, S., Hewer, A., and Phillips, D. H. Genotoxic potential of tamoxifen and analogues in female Fischer F344/N rats, DBA/2 and C57B1/G mice and in human MCL-5 cells. Carcinogenesis (Lond.), 13: 2197-2203, 1992.
15. Pathak, D. N., and Bodell, W. J. DNA adduct formation by tamoxifen with rat and human liver microsomal activation system. Carcinogenesis (Lond.), 15: 529-532, 1994.
16. Randerath, K., Bi, J., Mabon, N., Sriram, P., and Moorthy, B. Strong intensification of mouse hepatic tamoxifen DNA adduct formation by pretreatment with the sulfo-transferase inhibitor and ubiquitous environmental pollutant pentachlorophenol. Carcinogenesis (Lond.), 15: 797-800, 1994.
17. Lyman, S. D., and Jordan, V. C. Metabolism of non-steroidal antiestrogens. In: V. C. Jordan (ed.), Estrogen/antiestrogen Action and Breast Cancer Therapy, pp. 191-219. Madison, WI: The University of Wisconsin Press, 1986.
18. Foster, A. B., Griggs, L. J., Jarman, M., vanMaanen, M. S., and Schulten, H-R. Metabolism of tamoxifen by rat liver microsomes: formation of the oxide, a new metabolite. Biochem. Pharmacol., 29: 1977-1979, 1980.
19. Reunitz, P. C., Bagley, J. R., and Pape, C. W. Some chemical and biochemical aspects of liver microsomal metabolism of tamoxifen. Drug Metab. Dispos., 12: 478-483, 1984.
20. McCague, R., and Seago, A. Aspects of metabolism of tamoxifen by rat liver microsomes. Identification of a new metabolite: E-1-[4-(2-dimethyl aminoethoxy)-phenyl]-1,2-diphenyl-1-buten-3-o1-N-oxide. Biochem. Pharmacol., 35: 827-834, 1986.
21. Mani, C., Gelboin, H. V., Park, S. S., Pierce, R., Parkinson, A., and Kupfer, D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I: cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab. Dispos., 21: 645-656, 1993.
22. Nelson, D. R., Kamataki, T., Waxman, D. J., Guengerich, F. P., Estabrook, R. W., Feyereisen, R., Gonzalez, F. J., Coon, M. J., Gunsalus, I. C., Gotoh, O., Okuda, K., and Nebert, D. W. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol., 12: 1-51, 1993.
23. Jacolot, F., Simon, I., Dreano, Y., Beaune, P., Riche, C., and Berthou, F. Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem. Pharmacol., 41: 1911-1919, 1991.
24. Mani, C., Hodgson, E., and Kupfer, D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. II: flavin-containing monooxygenase-mediated N-oxidation. Drug Metab. Dispos., 21: 657-661, 1993.
25. AA as catalyst of 4-hydroxylation induced by TCDD and βNF. Cancer Res., 54: 3140-3144, 1994.
26. 14C]tamoxifen to liver microsomes and the forms of cytochrome P450 involved. Biochem. Pharmacol., 49: 1035-1042, 1995.
27. Blankson, E. A., Eills, S. W., Lennard, M. S., Tucker, G. T., and Rogers, K. The metabolism of tamoxifen by human liver microsomes is not mediated by cytochrome P450IID6. Biochem. Pharmacol., 42 (Suppl.): 5209-5212, 1991.
28. Styles, J. A., Davies, A., Lim, C. K., DeMatteis, F., Stanley, L. A., White, I. N. H., Yuan, Z-X., and Smith, L. L. Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis (Lond.), 15: 5-9, 1994.
29. Dehal, S. S., Richardson, T. H., Johnson, E. F., and Kupfer, D. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. In: Eleventh International Symposium on Microsomes and Drug Oxidations, p. 71. Los Angeles, 1996.
30. Crewe, H. K., Ellis, S. W., Lennard, M. S., and Tucker, G. T. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen in human liver microsomes. Biochem. Pharmacol., 53: 171-178, 1997.
31. Stresser, D. M., and Kupfer, D. Catalytic characteristics of CYP3A4: requirement for a phenolic function in ortho hydoxylation of estradiol and mono-O-demethylated methoxychlor. Biochemistry, 36: 2203-2210, 1997.
32. Borgna, J-L., and Rochefort, H. Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J. Biol. Chem., 256: 859-868, 1981.
33. Furr, B. J. A., and Jordan, V. C. The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther., 25: 127-205, 1984.
34. Pathak, D. N., Pongracz, K., and Bodell, W. J. Microsomal and peroxidase activation of 4-hydroxy-tamoxifen to form DNA adducts: comparison with DNA adducts formed in Sprague-Dawley rats treated with tamoxifen. Carcinogenesis (Lond.), 16: 11-15, 1995.
35. 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis (Lond.), 15: 2087-2094, 1994.
36. Moorthy, B., Sriram, P., Pathak, D. N., Bodell, W. J., and Randerath, K. Tamoxifen metabolic activation: comparison of DNA adducts formed by microsomal and chemical activation of tamoxifen and 4-hydroxytamoxifen with DNA adducts formed in vivo. Cancer Res., 56: 53-57, 1996.
37. Skoda, R. C., Gonzalez, F. J., Demierre, A., and Meyer, U. A. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc. Natl. Acad. Sci. USA, 85: 5240-5243, 1988.
38. Nebert, D. W. Polymorphism of human CYP2D genes involved in drug metabolism: possible relationship to individual cancer risk. Cancer Cells (Cold Spring Harbor), 3: 93-96, 1991.
39. Wolf, C. R., Smith, C. A. D., Gough, A. C., Moss, J. E., Vallis, K. A., Howard, G., Carey, F. J., Mills, K., McNee, W., and Carmichael, J. Relationship between the debrisoquine hydoxylase polymorphism and cancer susceptibility. Carcinogenesis (Lond.), 13: 1035-1038, 1992.
40. Furuya, H., Fernandez-Salguero, P., Gregory, W., Taber, H., Steward, A., Gonzalez, F. J., and Idle, J. R. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics. 5: 389-392, 1995.
41. Goldstein, J. A., and de Morais, S. M. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics, 4: 285-299, 1994.
42. Richardson, T. H., Jung, F., Griffin, K. J., Wester, M., Raucy,. J. L., Kemper, B., Bornheirn, L. M., Hassett, C., Omiecinski, C. J., and Johnson, E. F. A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in Escherichia coli. Arch. Biochem. Biophys., 323: 87-96, 1995.
43. Kupfer, D., and Dehal, S. S. Tamoxifen metabolism by microsomal cytochrome P450 and flavin-containing monooxygenase. In: E. F. Johnson and M. R. Waterman (eds.), Methods in Enzymology: Cytochrome P450 Part B. Vol. 272, pp. 152-163. New York: Academic Press, 1996.
44. Newton, D. J., Wang, R. W., and Lu, A. Y. Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos., 23: 154-158, 1995.
45. Holm, K. A., and Kupfer, D. Isolation by ion-exchange high performance liquid chromatography of rabbit liver cytochrome P-450 with regioselectivity for ω-hydroxylation of prostaglandins. J. Biol. Chem., 260: 2027-2030, 1985.
46. 5. J. Biol. Chem., 254: 11221-11229, 1982.
47. Malet, C., Compel, A., Spritzer, P., Bricout, N., Yaneva, H., Mowszowicz, I., Kuttenn, F., and Mayvais-Jarvis, P. Tamoxifen and hydroxytamoxifen isomers versus estradiol effects on normal human breast cells in culture. Cancer Res., 48: 7193-7199, 1988.
48. Vignon, F., Bouton, M-M., and Rochefort, H. Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens. Biochem. Biophys. Res. Commun., 146: 1502-1508, 1987.
49. Coezy, E., Borgna, J. L., and Rochefort, H. Tamoxifen and metabolites in MCF-7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res., 42: 317-323, 1982.
50. Wakeling, A. E., and Slater, S. R. Estrogen receptor binding and biologic activity of tamoxifen and its metabolites. Cancer Treat. Rep., 64: 741-744, 1980.
51. Katzenellenbogen, J. A., Carlson, K. E., and Katzenellenbogen, B. S. Facile geometric isomerization of phenolic non-steroidal estrogens and antiestrogens: limitations to the interpretation of experiments characterizing the activity of individual isomers. J. Steroid Biochem., 22: 589-596, 1985.
52. Harper, M. J. K., and Walpole, A. E. Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature (Lond.), 212: 87, 1966.
53. Williams, M. L., Lennard, M. S., Martin, I. J., and Tucker, G. T. Interindividual variation in the isomerization of 4-hydroxytamoxifen by human liver microsomes: involvement of cytochromes P450. Carcinogenesis (Lond.), 15: 2733-2738, 1994.
54. Hemminki, K., Rajaniemi, H., Lindahl, B., and Moberger, B. Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res., 56: 4374-4377, 1996.
55. Pathak, D. N., Pongracz, K., and Bodell, W. J. Activation of 4-hydroxytamoxifen and tamoxifen derivative metabolite E by uterine peroxidase to form DNA adducts: comparison with DNA adducts formed in the uterus of Sprague-Dawley rats treated with tamoxifen. Carcinogenesis (Lond.), 17: 1785-1790, 1996.
56. Wiseman, H., and Lewis, D. F. V. The metabolism of tamoxifen by human cytochrome P450 is rationalized by molecular modelling of the enzyme-substrate interactions: potential importance to its proposed anti-carcinogenic/carcinogenic actions. Carcinogenesis (Lond.), 17: 1357-1360, 1996.
57. Hildebrandt, A., and Estabrook, R. W. Evidence for the participation of cytochrome b5 in hepatic microsomal mixed-function oxidation reactions. Arch. Biochem. Biophys., 143: 66-79, 1971.
58. 5 in stimulation of catalytic activities of cytochrome P450 3A4. J. Biol. Chem., 271: 27438-27444, 1996.
59. Yamazaki, H., Nakano, M., Imai, Y., Ueng, Y-F., Guengerich, F. P., and Shimada, T. Roles of cytochrome b5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. Arch. Biochem. Biophys., 325: 174-182, 1996.
60. Poon, G. K., Chui, Y. C., McCague, R., Lonning, P. E., Feng, R., Rowlands, M. G., and Jarman, M. Analysis of phase I and phase II metabolites of tamoxifen in beast cancer patients. Drug Metab. Dispos., 21: 1119-1124, 1993.
61. Jordan, V. C., Collins, M. M., Rowsby, L., and Prestwich, G. A monohydroxylated metabolite of tamoxifen with potent antiestrogenic activity. J. Endocrinol., 75: 305-316, 1977.